# **Association of beta<sub>2</sub>-adrenergic** receptor gene polymorphisms and nocturnal asthma in Saudi patients

Abdullah M. Al-Rubaish

Department of Internal Medicine, King Fahad Hospital of the University, College of Medicine, University of Dammam, Dammam, Saudi Arabia

## Address for correspondence:

Dr. Abdullah M. Al-Rubaish, College of Medicine, University of Dammam, P.O. Box 1982, Dammam 31441, Saudi Arabia. E-mail: arubaish@ hotmail.com

> Submission: 08-01-11 Accepted: 06-02-10

Access this article online

Quick Response Code:

www.thoracicmedicine.org

10.4103/1817-1737.78416



**BACKGROUND AND OBJECTIVES:** Two polymorphisms of beta<sub>2</sub>-adrenergic receptor ( $\beta_2$ -AR) gene, namely the substitution from arginine (Arg) to glycine (Gly) at codon 16 and from glutamine (Gln) to glutamic (Glu) at codon 27, are linked with functional changes in the  $\beta_2$ -AR in the respiratory system even though they are not deemed to be susceptibility genes for asthma *per se*. The objective of this study was to investigate this association in a subset of asthmatic patients, namely those with nocturnal asthma.

**METHODS:** The  $\beta_2$ -AR gene polymorphisms at codon 16 and 27 were assessed in 40 patients clinically diagnosed with nocturnal asthma and 96 normal controls. Genomic DNA was obtained from whole blood and genotyping was carried out by a PCR based restriction fragment length polymorphism technique.

**RESULTS:** There was a statistically significant difference in genotype frequencies at codon 16 (Arg/Gly) between nocturnal asthmatic patients and normal control subjects (P < 0.05). However, there was no statistically significant difference in allele frequencies between the two groups. In addition, there was a significant association between Arg16-Gly genotype with nocturnal asthma compared to homozygous Gly16 (codominant model P = 0.0033, OR = 3.69: 95% CI: 1.49–9.12). However, there were no statistically significant differences in genotype and allele frequencies at codon 27 (Gln/Glu) between the normal control and nocturnal asthmatic groups ( $\chi^2 = 1.81$ , P = 0.41). The results also indicate that linkage disequilibrium existed between the  $\beta_2$ -AR codon 16 and  $\beta_2$ -AR codon 27 polymorphism (|D'| = 0.577). The data for all haplotypes did not show a statistically significant association.

**CONCLUSION:** We present the genotype and allele frequencies of  $\beta_2$ -AR gene polymorphisms in normal Saudi subjects and nocturnal asthmatic patients. There was a significant difference in genotype frequencies at codon 16 (Arg/Gly). However, our study indicates a poor association of individual single nucleotide polymorphisms with nocturnal asthma.

#### Key words:

Asthma,  $\beta_2$ -adrenergic receptor, frequency, polymorphism, Saudi Arabia

The gene for the human beta,-adrenergic L receptor ( $\beta_2$ -AR) is located on chromosome 5q31.<sup>[1]</sup> A number of single nucleotide polymorphisms (SNPs) in the  $\beta_2$ -AR gene have been identified.<sup>[2-4]</sup> The most frequent SNPs are due to two missense mutations, which occur in the coding region of the intronless  $\beta_2$ -AR gene. The first SNP (A > G) at nucleotide 46 causes the substitution of glycine (Gly) for arginine (Arg) at codon 16. The second SNP (C > G) at nucleotide 79 results in the substitution of glutamic (Glu) acid for glutamine (Gln) at codon 27. It has been reported that there are ethnic variations in the prevalence of these two  $\beta_2$ -AR SNPs.<sup>[5,6]</sup> Reports have indicated that these polymorphisms, which cause downregulation of the  $\beta_2$ -AR, play a significant role in bronchial asthma since they are linked with functional changes in the  $\beta_2$ -AR in the respiratory system.<sup>[6,7]</sup> A study by Reihsaus et al. and other studies found no difference in allele frequency of these two polymorphisms in patients with and without asthma.[2,8,9]

On the other hand, a number of studies

have shown that there is increased risk of asthma susceptibility in patients with these polymorphisms.<sup>[10-12]</sup> However, a meta-analysis study concluded that neither polymorphism influences the risk for asthma.<sup>[13]</sup> Subsequent studies have been performed to determine whether these polymorphisms influence more specific asthma phenotypes, such as the severe form of the disease or nocturnal asthma.<sup>[13–17]</sup> Nocturnal asthma constitutes a subset of asthma, which is associated with significant decline in pulmonary function and increase in airway inflammation at night.<sup>[18]</sup>

The Eastern Province of Saudi Arabia has one of the highest incidence rates of asthma in the Kingdom.<sup>[19,20]</sup> A study confirmed that asthma, chronic obstructive pulmonary disease, and pneumonia are the leading causes of hospitalization of patients with respiratory disorders in the Eastern Province.<sup>[20]</sup> The allele frequencies of these two polymorphic sites have been reported for the normal Saudi population.<sup>[5]</sup> The only existing report concerning

Website:

DOI:

the association of the prevalence of  $\beta_2$ -AR and asthma indicates that there is no statistically significant association between these polymorphisms and asthma *per se* in the population of the Eastern Province.<sup>[21]</sup> However, there have been reports concerning the association of these polymorphic sites with nocturnal asthma.<sup>[15-17]</sup> This prompted us to carry out this study to determine the prevalence of these polymorphic sites in normal Saudi individuals and patients with nocturnal asthma.

### **Methods**

Forty Saudi patients attending King Fahad Hospital of the University, Al-Khobar, Saudi Arabia over a period of one year between 2009 and 2010, who had been clinically diagnosed with nocturnal asthma were included in this case-control study. The participating patients were well-defined nocturnal asthmatics. It must be noted that this group of patients differs from those included in our previous asthma study. The control group was comprised of 96 subjects recruited from the general population, who were in the same age range. The sole exclusion criterion for control subjects was past, present or family history of asthma. All participants were requested to sign an informed written consent prior to participation in the study. Genomic DNA was obtained from 300 µL whole blood using QIAamp Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Genotypes of samples were determined using restriction fragment length polymorphism as described in the literature.<sup>[13]</sup> In brief, a 308 bp region of the  $\beta_2$ -AR gene spanning both polymorphic sites was amplified. The following primers 5'-CCT TCT TGC TGG CAC CCC AT-3' (sense) and 5'-GGA AGT CCA AAA CTC GCA CCA-3' (antisense) were used. The PCR reaction volume of 25 µL contained 100-250 ng of DNA, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTP, and 0.25 U Tag DNA polymerase in a standard PCR buffer. PCR cycles involved an initial 5 min at 94°C followed by 30 cycles at 94°C for 30 s, 58°C for 30 s, 72°C for 45 s, followed by a final extension at 72°C for 10 min. The PCR product was then digested with restriction enzyme NcoI for Arg16Gly and BbvI for the Glu27Gln polymorphism at 45°C for 1 h. Restriction products were separated on 3% agarose and visualized under UV illumination following ethidium bromide staining.

Genotype and allele frequencies were estimated by gene counting and expressed as percentages of the total. The  $\chi^2$ -test was used to compare differences between groups. A difference was considered statistically significant when P < 0.05. Statistical analysis Fisher's Exact test was used to test whether the frequency distribution of genotypes in the control group was in Hardy–Weinberg equilibrium (HWE). Linkage disequilibrium (LD), haplotypes frequencies estimation, and haplotypes association analysis were performed using the SNPStats web tool for association studies (http://bioinfo.iconcologia.net/SNPstats). The association was expressed as an odds ratio (OR) with the corresponding 95% confidence interval (95% CI).

### **Results**

A total of 136 samples from 40 patients and 96 age and gender matched controls were analyzed. Table 1 presents the baseline characteristics of the two study groups. The genotype distributions of both loci were in Hardy Weinberg equilibrium

# Table 1: Baseline characteristics of asthmatic patients and normal control subjects

	Control	Patients
Number	96	40
Age, mean ± SD (years)	12.6 ± 4.2 (range: 5–21 years)	11.4 ± 4.6 (range: 5–20 years)
Gender (males)	60.2%	54.8%
Duration of asthma	None	2–3 years
Severity of symptoms	None	Persistent cough at night
Frequency	None	3–4 times per week
FEV1	Normal	<60%
Treatment	None	Inhaled corticosteroids, salmeterol, and albuterol

in the control group (P = 0.057 for  $\beta_2$ -AR codon 16 and P = 0.178for  $\beta_2$ -AR codon 27). Table 2 presents the genotype and allele frequencies of  $\beta_2$ -AR gene polymorphism at codon 16 (Arg 16 Gly) in normal control and nocturnal asthmatic subjects. There was a statistically significant difference in genotype frequencies between patients with nocturnal asthma and normal control subjects (P < 0.05). However, there was no statistically significant difference in allele frequencies between the two groups. The data showed that there is a significant association between Arg16-Gly genotype with nocturnal asthma when compared to homozygous Gly16 (codominant model, P =0.0033, OR = 3.69; 95% Cl: 1.49-9.12). Table 3 summarizes the genotype and allele frequencies of  $\beta_2$ -AR polymorphism at codon 27 (Glu 27 Gln) in normal control and nocturnal asthmatic subjects. No significant statistical differences were found in genotype and allele frequencies between the normal control and nocturnal asthmatic groups ( $\chi^2 = 1.81$ , P > 0.4).

The results also indicate that linkage disequilibrium existed between the  $\beta_2$ -AR codon 16 and  $\beta_2$ -AR codon 27 polymorphism (|D'| = 0.577). The estimated frequencies for various haplotypes in both the control and patient groups and the significance of association with asthma are presented in Table 4. The data for all haplotypes did not show a statistically significant association.

#### Discussion

Asthma is a complex disease caused by interactions between many genes and environmental factors. Identification of the genetic basis of asthma may contribute to discovery of innovative asthma drugs. Nocturnal asthma represents a subset of asthmatic patients who usually experience worsening symptoms and the obstruction of airflow during the night.<sup>[18,22]</sup> Nocturnal asthma is a severe form of the disease and it is associated with increased morbidity, which has an extreme negative impact on the quality of life for patients. Patients with nocturnal asthma were generally found to have >15% decrease in lung function during the night.<sup>[22]</sup> A number of single nucleotide polymorphisms in the  $\beta_2$ -AR gene namely Arg/Gly at codon 16 and Gln/Glu at codon 27 have been implicated in asthma susceptibility.[10-12] A single amino acid substitution in the structural domains critical for receptor function has been shown to result in significant changes in receptor function.<sup>[7]</sup> However, these studies have generated conflicting results as to whether these genes alone confer a risk for

Genotype	Homozygous	Heterozygous	Homozygous	Total	P value
	arginine 16	Arg/Gly	glycine 16		
Normal	20 (20.8)	37 (38.6)	39 (40.6)	96	0.004
Nocturnal asthma	4 (10.0)	28 (70.0)	8 (20.0)	40	
Allele	Arginine 16	Glycine 16			
Normal	77 (40.1)	115 (59.9)		192	0.455
Nocturnal asthma	36 (45.0)	44 (55.0)		80	

Table 2: Distribution of genotype and allele frequencies of β-adrenergic receptor at codon 16 (Arg/Gly) in normal and nocturnal asthmatic subjects

Figures in parentheses are in percentage

# Table 3: Distribution of genotype and allele frequencies of $\beta$ -adrenergic receptor at codon 27 (Glu/Gln) in normal and nocturnal asthmatic subjects

Genotype	Homozygous glutamic 27	Heterozygous Glu/Gln	Homozygous glutamine 27	Total	P value
Normal	9 (9.5)	31 (32.6)	55 (57.9)	95	0.405
Nocturnal asthma	7 (17.5)	11 (27.5)	22 (55.0)	40	
Allele	Glutamic	Glutamine			
Normal	49 (25.8)	141 (74.2)		190	0.358
Nocturnal asthma	25 (31.2)	55 (68.8)		80	

Figures in parentheses are in percentage

# Table 4: Comparison of haplotypes frequencies betweenpatients and controls

Haplotype	Patients	Controls	Odds ratio (95% CI)	P value
AG	0.373	0.3661	Reference	
GG	0.3145	0.3795	0.83 (0.42 -1.65)	0.6
GC	0.2355	0.2186	0.99 (0.52 -1.92)	0.99
AC	0.077	0.0359	2.29 (0.48 –10.89)	0.3

asthma. Reports have indicated that Gly16 allele is associated with enhanced agonist-mediated downregulation of the receptor, while Glu27 allele enhances resistance to downregulation.<sup>[23,24]</sup> A meta-analysis study, which was composed of several thousand individuals, suggested that Arg/Gly polymorphism could possibly contribute to nocturnal symptoms in asthmatic patients.<sup>[13]</sup>

A study of the association of these two polymorphisms and asthma *per se* was recently concluded on a Saudi population residing in the Eastern Province.<sup>[21]</sup> This study showed that there was a significant difference in genotype frequencies at codon 16 (Arg16Gly) between asthmatic and normal control subjects (P < 0.05). However, there was no statistically significant difference in allele frequencies between the two groups (P > 0.05). In addition, when comparing the genotype and allele frequencies of Glu27Gln, no significant differences were observed between the asthmatic group and the normal control group.

In this study, we compared the allele frequencies of these two polymorphisms between normal and nocturnal asthmatic patients. There was a statistically significant difference in genotype frequencies at codon 16 (Arg16Gly) between nocturnal asthmatic patients and normal control subjects (P < 0.05). However, there was no statistically significant difference in allele frequencies between the two groups (P > 0.05). Our results of genotype frequencies of Arg16Gly polymorphism are in line with those of Kaisheng *et al.* who examined the frequency

of this polymorphic site of the  $\beta_2$ -AR gene in nocturnal asthmatic subjects.<sup>[15]</sup> It is also worth mentioning that there was no statistically significant difference in genotype or allele frequencies between the nocturnal asthmatic patients included in this study and the nocturnal asthmatic patients included in our previous study. When comparing the genotype and allele frequencies of Gln27Glu, no statistically significant differences were observed between the nocturnal asthmatic group and the normal control group (P > 0.05).

Previous reports have indicated that the interactions of multiple SNPs within a haplotype influence the phenotype more significantly that individual SNPs.<sup>[25]</sup> We examined the association of both SNPs and haplotypes with nocturnal asthma and concluded that there was no significant association.

In summary, we present the genotype and allele frequencies of  $\beta_2$ -AR gene polymorphisms in normal Saudi subjects and nocturnal asthmatic patients. There was a significant difference in genotype frequencies at codon 16 (Arg/Gly). However, our study indicates a poor association of individual single nucleotide polymorphisms with nocturnal asthma. Further studies are required to ascertain the interactions of different haplotypes and the response of patients with different haplotypes to various treatments.

### Acknowledgments

The author would like to extend his thanks and gratitude to the University of Dammam for the financial support of this project and Suad Al-Ateeq and Ali Radwan for technical assistance.

### References

- 1. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenegic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993;268:23116-21.
- 2. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the

gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334-9.

- 3. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994;33:9414-9.
- 4. Ober C, Hoffjan S. Asthma genetics 2006: The long and winding road to gene discovery. Genes Immun 2006;7:95-100.
- Maxwell TJ, Ameyaw MM, Pritchard S. Beta<sub>2</sub>-adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med 2005;16:573-80.
- Suarez EC, Saab PG, Llabre MM, Kuhn CM, Zimmerman E. Ethnicity, gender and age affects an adrenoceptors and physiological responses to emotional stress. Psychophysiology 2004;41:450-60.
- Green SA, Turki J, Bejarna P, Hall IP, Ligget SB. Influence of B<sub>2</sub>adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995;13:25-33.
- Dewar JC, Wheatley T, Venn A, Morrison JFJ, Britton J, Hall IP. B<sub>2</sub> adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in adult population. Clin Exp Allergy 1998;28:442-8.
- Binaei S, Christensen M, Murphy C, Zhang Q, Quasney M. Beta 2 adrenergic receptor polymorphisms in children with status asthmaticus. Chest 2003;123:375S.
- Gao G, Wang S, Zhang J. Study on beta 2 adrenergic receptor genetic polymorphisms in asthmatics in the people of the Han nationality of northern China. Zhonghua Jie He Hu Xi Za Zhi 2000;23:93-7.
- 11. Turner SW, Khoo SK, Laing IA, Palmer LJ, Gibson NA, Rye P, *et al.* Beta 2 adrenoceptor for Arg 16 Gly polymorphism airway responsiveness, lung function and asthma in infants and children. Clin Exp Allergy 2004;34:1043-8.
- Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, et al. Systematic review and meta-analysis of the association between B2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 2005;162:201-11.
- 13. Contopoulos-loannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association of beta-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005;115:963-72.
- 14. Holloway JW, Dunbar PR, Riley GA, Sawyer GM, Fitzharris

PF, Pearce N, *et al*. Association of  $\beta$ -2 adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2002;30:1097-103.

- 15. Kaisheng Y, Xilong Z, Yuying Q. Association between  $\beta_2$ adrenergic receptor genetic polymorphism and nocturnal asthmatic patients of Chinese Han Nationality. Clin Invest 2006;73:464-7.
- 16. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of beta<sub>2</sub>-adrenergic receptor in nocturnal and nonnocturnal asthma: Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995;95:1635-41.
- Kim SH, Oh SY, Oh HB, Kim YK, Cho SH, Kim YY, et al. Association of beta2-adrenoreceptor polymorphisms with nocturnal cough among atopic subjects but not with atopy and nonspecific bronchial hyperresponsiveness. J Allergy Clin Immunol 2002;109:630–5.
- 18. Calhoun WJ. Nocturnal Asthma. Chest 2003;123:399S-405S.
- Al-Frayh A, Benar AB, Al-Jawadi TQ. Prevalence of asthma among Saudi children. Saudi Med J 1992;13:521-4.
- Alamoudi OS. Prevalence of respiratory diseases in hospitalized patients in Saudi Arabia: A 5 years study 1996-2000. Ann Thorac Med 2008;1:76-80.
- 21. Al-Rubaish AM.  $\beta_2$ -adrenergic receptor gene polymorphisms in normal and asthmatic individuals in the Eastern province of Saudi Arabia. Ann Saudi Med 2011 [In Press].
- 22. Salas Hernández J, Fernández Vega M, Almeida Arvizu VM. Asthma classification. Rev Alerg Mex 2009;56:S58-63.
- 23. Hall IP. Beta2-adrenoceptor polymorphisms and asthma. Clin Exp Allerg 1999;29:1151-4.
- 24. Hall IP. Genetics and pulmonary medicine: Asthma. Thorax 1999;54:65-9.
- Carroll CL, Stoltz P, Schramm CM, Zucker AR. β2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 2009;135:1186-92.

**How to cite this article:** AI-Rubaish AM. Association of beta<sub>2</sub>-adrenergic receptor gene polymorphisms and nocturnal asthma in Saudi patients. Ann Thorac Med 2011;6:66-9.

Source of Support: University of Dammam, Conflict of Interest: None declared.

### New features on the journal's website

#### Optimized content for mobile and hand-held devices

HTML pages have been optimized of mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed. Click on [Mobile Full text] from Table of Contents page.

This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version)

#### E-Pub for hand-held devices

EPUB is an open e-book standard recommended by The International Digital Publishing Forum which is designed for reflowable content i.e. the text display can be optimized for a particular display device.

Click on [EPub] from Table of Contents page.

There are various e-Pub readers such as for Windows: Digital Editions, OS X: Calibre/Bookworm, iPhone/iPod Touch/iPad: Stanza, and Linux: Calibre/Bookworm.

### E-Book for desktop

One can also see the entire issue as printed here in a 'flip book' version on desktops. Links are available from Current Issue as well as Archives pages. Click on 🚳 View as eBook